|Dr. George M. Lasezkay J.D., Pharm.D., Pharma.D.||Pres, CEO & Director||836k||N/A||1952|
|Mr. Charles A. Deignan||Chief Financial Officer||510.81k||N/A||1964|
|Dr. Thomas A. Ciulla M.B.A., M.D.||Chief Medical Officer & Chief Devel. Officer||589.77k||N/A||1964|
|Ms. Jenny R. Kobin||Head of Investor Relations||N/A||N/A||1967|
|Mr. Rick McElheny||VP of Corp. Devel.||N/A||N/A||N/A|
|Ms. Susan L. Coultas Ph.D.||Chief Clinical Officer||N/A||N/A||N/A|
|Mr. Leslie B. Zacks||Sec.||N/A||N/A||1969|
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.
Clearside Biomedical, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.